参考文献/References:
[1]Dagenais GR,Leong DP,Rangarajan S,et al. Variations in common diseases,hospital admissions,and deaths in middle-aged adults in 21 countries from five continents (PURE):a prospective cohort study[J]. The Lancet,
[2]中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2014 [J]. 中华心血管病杂志,2014,2(2):98-122.
[3]Lytvyn Y,Bjornstad P,Udell JA,et al. Sodium glucose cotransporter-2 inhibition in heart failure:potential mechanisms,clinical applications,and summary of clinical trials[J]. Circulation,2017,136(17):1643-1658.
[4]朱路,李华荣. 达格列净:中国的首个SGLT2抑制剂[J]. 实用药物与临床, 2017，20(11):120-123.
[5]Wilding J,Fernando K,Milne N,et al. SGLT2 inhibitors in type 2 diabetes management:key evidence and implications for clinical practice[J]. Diabetes Ther,2018,9(5):1757-1573.
[6]高斯德. 钠-葡萄糖协同转运蛋白抑制剂心力衰竭的研究进展[J]. 心血管病学进展,2018,(5):703-708.
[7]Meng W,Ellsworth BA,Nirschl AA,et al. Discovery of dapagliflozin:a potent,selective renal sodium-dependent glucose cotransporter 2(SGLT2) inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2008,51(5):1145-1149.
[8]Komoroski B,Vachharajani N,Feng Y,et al. Dapagliflozin,a novel,selective SGLT2 inhibitor,improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus[J]. Clin Pharmacol Ther,2009,85(5):513-519.
[9]Zhang N,Feng B,Ma X,et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol,2019,18(1):107.
[10]Kato ET,Silverman MG,Mosenzon O,et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation,2019,139(22):2528-2536.
[11]Maack C,Lehrke M,Backs J,et al. Heart failure and diabetes:metabolic alterations and therapeutic interventions:a state-of-the-art review from the translational research committee of the heart failure association-european society of cardiology[J]. Eur Heart J,2018,39(48):4243-4254.
[12]Baartscheer A,Schumacher CA,Wüst RC,et al. Empagliflozin decreases myocardial cytoplasmic Na+through inhibition of the cardiac Na+/H+exchanger in rats and rabbits[J]. Diabetologia,2017,60(3):568-573.
[13]Dekkers CCJ,Sj?str?m CD,Greasley PJ,et al. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes[J]. Diabetes Obes Metab,2019,21(12):2667-2673.
[14]Koutroumpakis E,Jozwik B,Aguilar D,et al. Strategies of unloading the failing heart from metabolic stress[J]. Am J Med,2020,133(3):290‐296.
[15]Sano M,Takei M,Shiraishi Y,et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys[J]. J Clin Med Res,2016,8(12):844-847.
[16]Mudaliar S,Alloju S,Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis[J]. Diabetes Care,2016,39(7):1115-1122.
[17]Maack C,Lehrke M,Backs J,et al. Heart failure and diabetes:metabolic alterations and therapeutic interventions:a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology[J]. Eur Heart J,2018,39(48):4243-4254.
[18]Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion[J]. Cardiovasc Diabetol,2019,18(1):129.
[19]Kato ET,Silverman MG,Mosenzon O,et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation,2019,139(22):2528-2536.
[20]Wiviott SD,Raz I,Bonaca MP,et al. The design and rationale for the dapagliflozin effect on cardiovascular events(DECLARE)-TIMI 58 Trial[J]. Am Heart J,2018,200:83-89.
[21]Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.
[22]Pasternak B,Ueda P,Eliasson B,et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure:scandinavian register based cohort study[J]. BMJ,2019,366:l4772.
[23]Zelniker TA,Wiviott SD,Raz I ,et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet,2019,393(10166):31-39.
[24]McMurray JJV,Solomon SD,Inzucchi SE,et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,381(21):1995‐2008.
[25]Salehi T,Coates PT. Class effect:dapagliflozin reduces cardiovascular and kidney events[J]. Kidney Int,2020,97(2):246-248.
[26]Alba M,Xie J,Fung A,et al. The effects of canagliflozin,a sodium glucose co-transporter 2 inhibitor,on mineral metabolism and bone in patients with type 2 diabetes mellitus[J]. Curr Med Res,2016,32(8):1375-1385.
[27]Chang HY,Singh S,Mansour O,et al. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes[J]. JAMA Intern Med,2018,178(9):1190-1198.
[28]Bonner C,Kerr-Conte J,Gmyr V,et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion[J]. Nat Med,2015,21(5):512-517.
[29]Thong KY,Yadagiri M,Barnes DJ,et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment:the ABCD nationwide dapagliflozin audit[J]. Prim Care Diabetes,2018,12(1):45-50.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(8):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(8):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(8):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(8):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(8):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(8):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]